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Abstract
Background: Transmission of human immunodeficiency virus type 1 (HIV-1) through breast-feeding may involve
both cell-free and cell-associated virus. This latter viral reservoir remains, however, to be fully explored. CD4
+ T cell-
associated virus production in breast milk was therefore investigated.
Methods: The ex vivo spontaneous production of HIV-1 antigen and HIV-1 RNA by CD4
+ T cells was measured in
paired blood and breast milk samples from 15 HIV-1 infected women treated or not with antiretroviral drugs.
Spontaneous antigen secreting cells (HIV-1-AgSCs) from breast milk and blood were enumerated by an ELISpot
assay, and cell-associated HIV-1 RNA was quantified by real-time PCR in supernatants of CD4
+ T cells cultured for
18 hours without addition of polyclonal activators.
Results: Among the CD4
+ T cells present in breast milk, memory cells expressing high levels of cell-surface
activation markers were predominant. Spontaneous HIV-1-AgSCs were detected and enumerated in the breast milk
of all 15 women, with a median number of 13.0 and 9.5 HIV-1- AgSCs/106 CD4
+ T cells in aviremic (n = 7) and
viremic (n = 8) women, respectively. Cell- associated HIV-1 RNA was detected in cell-free supernatants from 4/7
aviremic and 5/8 viremic individuals at median levels of 190 and 245 copies/ml, respectively.
Conclusions: Activated CD4
+ T cells producing HIV-1 are detected in the breast milk of untreated individuals as
well as those receiving highly active antiretroviral therapy. This finding strongly suggests that HIV-1 replication
occurs in latently infected CD4
+ T cells that, upon spontaneous activation, revert to productively infected cells.
These cells might be responsible for a residual breast milk transmission despite maternal highly active antiretroviral
therapy.
Background
Today, while improvements have been made in prophy-
lactic measures to prevent the perinatal transmission of
HIV-1, its transmission through breastfeeding is still the
cause of over half the estimated yearly 420,000 new
pediatric infections worldwide [1]. Indeed, while it is
universally recognized as the optimal source of nutrition
and defense against disease in infants, breast milk is also
a major mode of HIV-1 transmission from mother to
child [2-4]. The mechanisms by which this occurs,
however, remain poorly understood [5]. In breast milk,
HIV-1 may be present in three different forms of poten-
tially unequal transmission risk: (i) free virions measured
as HIV-1 RNA, (ii) integrated provirus measured as
HIV-1 DNA, and (iii) HIV-1 RNA that is released by
activated cells that sustain the virus replication cycle
and is measured as cell-associated HIV-1 RNA. High
levels of free HIV-1 RNA in maternal plasma and in
breast milk are associated with a high risk of breastfeed-
ing transmission [6-11]. A similar association has been
demonstrated with HIV-1 proviral DNA levels in breast
milk, thus suggesting that both cell-free and cell-asso-
ciated HIV-1s are involved in breastfeeding transmission
[9,12-14]. Results of a study performed in Botswana
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mainly transmitted by cells containing the provirus
while the cell-free virus is more frequently involved later
on [15]. Furthermore, preliminary observations suggest
that some babies breastfed by HIV-1 infected women
taking antiretroviral therapy (ART) get infected despite
undetectable levels of HIV-1 RNA in their mother’s
plasma or breast milk [16,17]. Importantly, the in vitro
infectivity of the cell-associated virus has been found to
be 100 to 1000 times higher than that of cell-free virus
stocks [18]. Taken together, these observations strongly
suggest that cell-associated virus is frequently involved
in the transmission of HIV-1 by breastfeeding. HIV-1
persists in a latent form in resting CD4
+ T cells, even in
patients receiving antiretroviral treatment (ART) and in
whom the viral load is undetectable. These latently
infected cells constitute a viral reservoir, which may be
regarded as a cell type or anatomical site in which a
functional form of the virus persists with increased sta-
bility compared to the pool of actively replicating virus
[19]. A recent study shows that cell-free and, to a much
lesser extent, cell-associated HIV-1 RNA levels in breast
milk are suppressed by antiretroviral regimens used to
prevent mother to child transmission, whereas no signif-
icant reduction in latently HIV-1 infected resting CD4
+
T cells is observed [20].
We recently demonstrated that breast milk contains
such resting CD4
+ T lymphocytes and that these cells
are capable of producing viral antigens (Ags) and virions
after in vitro polyclonal-cell activation. In addition, these
CD4
+ T lymphocytes showed a greater capacity to pro-
duce viral particles than their circulating blood counter-
parts [21]. Moreover, it has also been demonstrated that
CD4
+ T cells from most viremic HIV-1 infected
patients, spontaneously secrete HIV-1 virions as a con-
sequence of an ongoing viral replication in the absence
of ART or a residual HIV-1 replication under ART
[22,23]. Thus, we hypothesized that breast milk contains
CD4
+ T cells able to spontaneously produce HIV-1 pro-
teins, RNA. and infectious particles.
In this study, we (i) characterized activated CD4
+ T
cells in breast milk, (ii) enumerated CD4
+ T cells sponta-
neously producing HIV-1 antigens (HIV-1-AgSCs), and
(iii) measured cell-associated HIV-1 RNA in cell-free
supernatants in infected women treated or not with anti-
retroviral drugs. The human milk-derived activated CD4
+
T cells that spontaneously produced HIV-1 were barely
affected by maternal antiretroviral therapy and might
therefore be responsible for residual HIV-1 transmission.
Results
Study subjects
Women’s characteristics, antiretroviral treatments and
breast milk sample collection conditions are described
in Table 1. According to national policy guidelines, 9
women received perinatal prophylactic treatment to pre-
vent mother to child transmission of HIV-1, consisting
of zidovudine given from between the 34th and 36th
weeks of pregnancy until delivery plus a single dose of
nevirapine during labor/delivery. The remaining 6
women were eligible for ART during pregnancy and
received zidovudine, lamivudine and ritonavir-boosted
lopinavir. The mean duration of ART until delivery was
36.4 days. Among the 15 women, the mean CD4
+ T cell
count was 519 cells/mm3 and the mean plasma HIV-1
RNA level 13,105 copies/ml. Seven women, 5 treated
with ART (nos. 1, 3, 9, 12 and 13) and two with the
short perinatal prophylactic treatment (nos. 6 and 11),
had undetectable plasma HIV-1 RNA load. The remain-
ing seven women who received the short perinatal pro-
phylactic treatment (nos. 2, 4, 5, 7, 10, 14 and 15) had a
detectable plasma HIV-1 RNA load, and the one
remaining woman receiving ART (no. 8) showed detect-
able viraemia. HIV-1 RNA was detected in the breast
milk of five (35%) women; (mean 140 HIV-1 RNA
copies/ml, range < 145-4,062 HIV-1 RNA copies/ml),
four of whom had stopped ART at time of sampling
and showed detectable HIV-1 plasma viral load.
Characterization of CD4
+ T cells in breast milk
As shown in one representative case (patient no. 10), we
characterized the CD3
+, CD4
+ and CD8
+T cells as well as
CD4
+ and CD8
+ T cells expressing HLA-DR and CD38
receptors in breast milk and blood by flow cytometry
prior to CD4
+ Tc e l le n r i c h m e n t( F i g u r e1 A ,B ,C ) .T h e
CD4
+ T cells in the breast milk of 15 women represented
on average 22.2% of the total T cell count, and the CD3
+
CD8
+ T cells represented 60.1%. A similar distribution
was found in blood samples. The majority of CD4
+ and
CD8
+ T cells in milk did not express the CD45RA recep-
tors characteristic of naive T cells (mean 92.4% and 79%,
respectively). The percentage of CD4
+ and CD8
+ T cells
not expressing CD45RA was significantly lower in blood
(mean 64.3% and 45.3%, respectively, P < 0.001). These
results imply that the majority of T cells found in the
milk are mainly memory T cells. This observation was
confirmed by the high level of cell-surface CD45RO
receptor expression on these cells (data not shown). In
a d d i t i o n ,a ss h o w ni nT a b l e2 ,b r e a s tm i l kC D 4
+ and
CD8
+ T cells expressed higher levels of activation mar-
kers when compared with blood CD4
+ and CD8
+ Tc e l l s .
Thus, breast milk from HIV-1 infected women contains
predominantly activated memory CD4
+ T cells.
Enumeration of HIV-1-AgSCs in breast milk and blood
derived CD4
+ T cells
To evaluate the ability of the CD4
+ T lymphocytes to
spontaneously secrete HIV-1 Ag and viral particles, freshly
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+ T cells from paired breast milk and blood
samples were directly tested using our ELISpot assay.
HIV-1-AgSCs were detected in breast milk cells from all
women. As shown in Figure 2, the median number of
HIV-1-AgSCs was similar in aviremic (n = 7) and viremic
(n = 8) subjects, 13.0 HIV-1-AgSCs/10
6 CD4
+ T cells
[Interquartile Range (IQR) 9.5-16.5 HIV-1- AgSCs/10
6
CD4
+ T cells] and 9.5 HIV-1-AgSCs/10
6 CD4
+ Tc e l l s
(IQR 8.1-29.4 HIV-1-AgSCs/10
6 CD4
+ T cells), respec-
tively (P > 0.05). HIV-1-AgSCs were also detected in the
blood of viremic and aviremic women, median, 8.1/10
6
CD4
+ T cells (IQR, 4.0-9.5/10
6 CD4
+ T cells) and 6.25/10
6
CD4
+ T cells (IQR, 5.4-10.3/10
6 CD4
+ T cells, respec-
tively), the numbers of which showed no significant differ-
ence between the two groups (P > 0.05).
Detection of cell-associated HIV-1 RNA in supernatants
from breast milk- and blood-derived CD4
+ T cell cultures
HIV-1 RNA was also quantified in the culture supernatant
following 18 hours culturing of breast milk- and blood-
derived CD4
+ T cells. As shown in Figure 3, concerning
the breast milk samples, breast milk cell-associated HIV-1
RNA was detectable in 10 of the 15 subjects (66.7%), the
HIV-1 RNA levels were similar in women with detectable
or undetectable plasma viral load: median, 245 RNA
copies/ml (IQR, 113-12,300 RNA copies/ml) and 190
RNA copies/ml (IQR, 30-261 copies/ml), respectively. No
correlation was observed between the number of HIV-1
RNA copies detected in the supernatants and the number
of HIV-1-AgSCs. These data suggest that the presence of
cells spontaneously producing HIV-1 RNA in breast milk
is independent of plasma HIV-1 RNA levels. In blood
samples, cell-associated HIV-1 RNA was detected in 14/15
individuals (93.3%) with a median level of 2,261 RNA
copies/ml (IQR, 1,629-5,190 RNA copies/ml) in aviremic
women (range 583-119,981) and 13,855 (IQR, 40,051-
111,390 RNA copies/ml) in viremic women. Unexpectedly,
although a similar number of HIV-1-AgSCs was found in
the breast milk of aviremic and viremic women, the cell-
associated HIV-1 RNA copies were significantly higher in
the women with detectable viral load (P <0 . 0 1 ) .C D 4
+ T
cell-associated HIV-1 RNA levels were significantly higher
Table 1 Characteristics of HIV-1 infected women
Patients
no.
Initiation of
antiretroviral treatment
(days before delivery)
Duration of lactation until
sampling (days)
Antiretroviral
regimen
Treatment at time
of sampling
CD4
+ T cell
counts/mm
3
HIV-1 RNA level
(copies/ml)
plasma Breast
milk
1 15 54 ART
a Ongoing NT ND
b NT
2 18 65 Short-course
prophylaxis
c
Withdrawal since 65
days
400 1776 ND
3 34 33 ART Ongoing 762 ND ND
4 35 11 Short-course
prophylaxis
Withdrawal since 11
days
521 12,878 ND
5 38 14 Short-course
prophylaxis
Withdrawal since 14
days
270 83,547 ND
6 26 55 Short-course
prophylaxis
Withdrawal since 55
days
646 ND ND
7 47 57 Short-course
prophylaxis
Withdrawal since 57
days
658 6,790 ND
8 32 50 ART Ongoing 305 34,937 4,062
9 17 29 ART Ongoing 416 ND ND
10 65 91 Short-course
prophylaxis
Withdrawal since 91
days
628 50,036 772
11 58 77 Short-course
prophylaxis
Withdrawal since 77
days
618 ND 190
12 15 52 ART Ongoing 444 ND ND
13 69 21 ART Ongoing 533 ND ND
14 46 9 Short-course
prophylaxis
Withdrawal since 9
days
688 1,049 145
15 31 15 Short-course
prophylaxis
Withdrawal since 15
days
384 4,526 308
aART, antiretroviral therapy.
bThreshold: 300 copies/ml plasma and 60 copies/ml for breast milk.
cShort-course perinatal prophylaxis (zidovudine until delivery and a single-dose of nevirapine during labor).
NT: not tested.
ND: not detected, < threshold.
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undetectable HIV-1 viral load in plasma and breast milk
(n = 5), both cell-associated HIV-1 RNA and HIV-1-
AgSCs were detected in the breast milk, suggesting that
the antiretroviral treatment was not fully effective at sup-
pressing spontaneous virus production in breast milk.
In vitro infection of CD4
+ T cells using breast milk- and
blood-cell culture supernatants
The infectivity of the virus secreted in breast milk- and
blood- cell culture supernatants was assessed by
infection of in vitro activated CD4
+ T cells provided by
healthy blood donors. As shown in Figure 4, a decrease
in HIV-1 RNA levels, followed by a sustained rebound
of HIV-1 RNA, was observed in three blood-derived
supernatants and two breast milk-derived supernatants,
demonstrating the infectiousness of the virus. Successful
in vitro infections were obtained using samples from
women not receiving ART. The resulting supernatant
fluids exhibited a viral load of over 10,000 copies/ml
after 18 hours of CD4
+ T cell incubation. Within the
first few days of in vitro infection, we observed a
26.2% 59.3%
2.2% 12.3%
Breast milk CD4+ T cells
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Figure 1 Representative dot plots from breast milk and blood samples of an HIV-1-infected woman (no 8) (A) Gating strategy to
explore breast milk CD4
+ T cells and CD8
+ T cells.( B) Analysis of CD38 and HLA-DR cell-surface expression on breast milk CD4
+ T cells (left)
and CD8
+ T cells (right). (C) CD38 and HLA-DR cell surface expression on blood CD4
+ T cells (left) and CD8
+ T cells (right) using the same gating
strategy. The percentage of cells positive for both HLA-DR and CD38 staining is given in the upper quadrant of each dot plot.
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Page 4 of 12decrease in HIV-1 viral load in the breast milk derived
supernatant. This may be related to the membrane fixa-
tion and entry of the HIV-1 into the target cells before
completion of the virus cycle. The decline in viral load
appears less visible during the first few days of target
cell culture with blood-derived compared to breast
milk-derived supernatant. This may be related to the
higher HIV-1 viral load in blood supernatant for the
same number of target CD4
+ cells.
Quantification of HIV-1 DNA in breast milk- and blood-
derived CD4
+ T cells
HIV-1-proviral DNA was measured in 12 of the 15
breast milk samples. The median HIV-1 DNA level was
3,178 DNA copies/10
6 CD4
+ T cells (IQR, 460-23,646
DNA copies/10
6 CD4
+ T cells) and showed no signifi-
cant difference between aviremic- and viremic-women.
HIV-1 DNA was also detected in the circulating CD4
+
T cells of the same 12 subjects, median 23,310 copies/
10
6 CD4
+ T cells (IQR, 1,875-117,886 copies/10
6 CD4
+
T cells), again with no significant difference between
aviremic versus viremic subjects.
Discussion
To investigate the cells potentially involved in HIV-1
postnatal transmission through breastfeeding, freshly
purified breast milk CD4
+ T cells were enumerated and
characterized for their capacity to spontaneously pro-
duce HIV-1 Ag, using a sensitive HIV-1 Ag ELISpot
assay. In parallel, after an overnight cell-culture step,
Table 2 Cell-surface marker expression on breast milk
and blood T lymphocytes
Cell-surface marker Breast milk Blood P
CD3
+ CD4
+ 22.2 (4.1-62.3)
a 29.2 (10.6-46.0) NS
b
CD3
+CD8
+ 60.1 (18.7-83.4) 56.3 (39.1-82.7) NS
CD4
+ CD45RA
- 92.4 (64.2-98.1) 64.3 (43.4-88.1) < 0.001
CD8
+ CD45RA
- 79.0 (69.6-99.3) 45.4 (25.3-72.5) 0.003
CD4
+ HLA-DR
+ 42.6 (19.2-87.5) 12.0 (1.0-18.1) 0.004
CD4
+ CD38
+ 39.2 (22.1-72.8) 51.3 (24.5-81.2) NS
CD4
+ CD38
+ HLA-DR
+ 23.3 (12.6-46.6) 8.1 (0.3-15.3) 0.01
CD8
+ HLA-DR
+ 76.4 (24.5-89.2) 20.6 (11.5-45.9) < 0.001
CD8
+ CD38
+ 92.5 (45.4-98.2) 54.2 (27.2-99.8) < 0.001
CD8
+ CD38
+ HLA-DR
+ 72.3 (16.3-95.6) 11.7 (9.3-43.2) < 0.001
amean (range).
bNS, not significant
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Figure 2 Detection of ex vivo HIV-1 Ag secreting CD4
+ T lymphocytes in breast milk and blood.H I V - 1i n f e c t e dC D 4
+ T cells able to
spontaneously produce HIV-1 Ag were enumerated by an ELISpot assay aimed at detecting p24 secretion. Spontaneous HIV-1-AgSCs were
detected in breast milk cell samples from all the women tested. Dotted line indicates the lower limit of quantification of the test (3 HIV-1-AgSCs/
10
6 CD4
+ T cells). The number of HIV-1-AgSCs showed no significant difference between individuals in whom plasma HIV-1 RNA was detectable
or not nor was any difference found between breast milk and blood compartments (Mann Whitney U test, P > 0.05).
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culture supernatants.
We have demonstrated that the majority of breast
milk CD4
+ T cells express low levels of CD45RA recep-
tors and, concomitantly, high levels of HLA-DR and
CD38 markers thus allowing them to be considered as
being activated. While liquid nitrogen conservation and
thawing may slightly modify the expression of cell sur-
face markers on T lymphocytes [24], this cannot
account for the large differences observed between CD4
+ T cells derived from blood and those from breast
milk. In addition, the level of CD38 and HLA-DR
expression observed in this study were 194 similar to
those previously observed in fresh blood- and breast
milk-derived T cells [25]. These data clearly indicate
that a large fraction of CD4
+ T cells present in the
breast milk of HIV-1 infected women comprise activated
memory T cells. This is consistent with the physiological
role of breast milk as a source of immunologically active
cells [21,25-27], and suggests a minimal, if any, blood
CD4
+ T cell contamination since the peripheral CD4
+ T
cells are mainly naive. Breast milk lymphocytes may
become highly activated during extravasation and/or
transepithelial migration, or by exposure to the cyto-
kines and chemokines contained in the breast milk
micro environment [28-31].
In the second step of our study, freshly purified CD4
+
T cells from paired breast milk and blood samples of
HIV-1 infected women were assayed for cell associated
virus production using an ELISpot assay to analyze p24
secretions at the single cell level. We also quantified
HIV-1 RNA levels after a short period of culture of CD4
+ T cells without the addition of polyclonal activators.
We and others have previously shown that HIV-1
latently infected CD4
+ T cells derived from blood and
breast milk are able to sustain the viral cycle and pro-
duce viral antigens and virions, following their polyclo-
nal activation in vitro [21,32-34]. In vivo,s o m eo ft h e
HIV-1 latently infected breast milk-derived CD4
+ T cells
may revert to productively infected lymphoblasts if they
are able to survive for an extended period of time in the
g u to rb o d yo ft h ei n f a n t .H o w e v e r ,i ns u b j e c t s
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Figure 3 Cell-associated HIV-1 RNA from breast milk and blood derived CD4
+ T cell culture supernatants. HIV-1 RNA was quantitated in
cell-free culture supernatant following 18 hours of incubation. Results from breast milk and blood cells were separated according to the
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Page 6 of 12untreated by ARV, the vast majority of the virus is pro-
duced by activated CD4
+ T cells that play a key role in
H I V - 1t r a n s m i s s i o n .T h e s ec e l l sh a v eav e r ys h o r th a l f -
life, surviving only about 1 day before dying as the result
of viral cytopathic effects or the host cytolytic effector
response. The present study provides evidence of the
existence of HIV-1 productively infected cells in breast
milk. P24 and HIV-1 secretion were detectable after
only a short period of culture demonstrating that these
breast milk-derived activated CD4
+ T cells constitute a
replication-competent form of the HIV-1 cell reservoir.
Given the fact that a majority of CD4
+ Tc e l l si nb r e a s t
milk are physiologically activated in HIV-1 infected
individuals, we hypothesized that some of the breast
milk-derived T cells latently infected by HIV-1 revert to
productively infected cells upon activation in the mam-
mary gland. This could explain why HIV-1-AgSCs were
found in the breast milk of all the women tested. As the
number of immunospots (each one representing one
HIV-1-secreting CD4
+ T cell) was similar in aviremic
and viremic women, we can infer that the presence of
H I V - 1 - A g S C si nb r e a s tm i l ki sn o tr e l a t e dt op l a s m a
HIV-1 load. We assume that our observations reflect
the particular dynamics of HIV-1 replication within the
mammary gland and the existence of a functional reser-
voir probably involved in virus transmission through
breast-feeding. On the other hand, the culture condi-
tions used in this study cannot be considered as repre-
sentative of the complex network involved in breast
milk transmission that includes the gut and MALT of
the infants. Cytotoxic T lymphocytes are associated with
the control of HIV-1 and SIV viremia [35]. Studies have
demonstrated that HIV-1-specific cytotoxic CD8
+ T
cells are present in the breast milk of infected women
w h e r et h e ym a yh a v eac r i t i c a lr o l eo fl i m i t i n gH I V - 1
replication within the mammary gland [25]. The deple-
tion of CD8
+ T cells performed in our study likely
diminished any HIV-1 specific response and therefore
potentially facilitated the HIV-1 secretion in vitro.
The fact that HIV-1-AgSCs were also detected in
breast milk samples with undetectable HIV-1 RNA sug-
gests that HIV-1-AgSCs release insufficient levels of
HIV-1 RNA for detection and/or that the time of transit
of these cells into the breast milk is too short to allow
HIV-1 RNA to be detected in breast milk. In women
with successful ART, undetectable HIV-1 RNA in both
plasma and breast milk has been interpreted as reflect-
ing the cessation of viral replication within maternal
lymphoid tissues [36,37] along with that in the mam-
mary gland [38]. All but one woman receiving ART had
undetectable plasma and breast milk HIV-1 RNA loads
indicating the effectiveness of treatments on cell free
HIV-1. The high viral load observed in plasma from one
woman (no. 8) after more than 2 months of ART sug-
gests a default in observance or the development of
HIV-1 resistance to antiretroviral drugs. While ART has
been associated with a dramatic decrease in HIV-1 RNA
levels and, to a lesser extent, in HIV-1 DNA levels [12]
in blood and breast milk, its impact on cell associated
HIV-1 RNA has been proposed as being only moderate
[20]. This cell-associated HIV-1 RNA might therefore
constitute a source of HIV-1 transmitted by breastfeed-
ing women successfully treated with ART [16].
In the third experimental step, we showed that cells
characterized and enumerated by the HIV-1- Ag ELI-
Spot assay also secrete HIV-1 particles, since the major-
ity of breast milk and blood culture supernatants
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Figure 4 Co-culture of breast milk- and blood-cell viral-culture
supernatants with CD4
+ T cells. The infectivity of virus secreted
into culture supernatants was tested after 18 h of incubation by co
culturing with phytohemagglutinin-activated CD4
+ T cells from
healthy blood donors. A) HIV-1 RNA quantification in CD4
+ T co-
culture with breast milk cell supernatants. B) HIV-1 RNA
quantification in CD4
+ T co-culture with blood cell supernatants.
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Page 7 of 12contained infectious HIV-1 RNA. Surprisingly, the levels
of HIV-1 RNA were significantly higher in supernatants
of cultured blood CD4
+ T cells as compared to cultured
breast milk CD4
+ T cells, particularlyi nH I V - 1v i r e m i c
individuals. Pretreatment of CD4
+ T cells with pronase
before testing to characterize the cellular HIV-1 RNA
secretion [22] revealed that blood CD4
+ T cells passively
release high levels of cell-bound membrane HIV-1 parti-
cles upon incubation. In addition, the ex vivo detection
of cell-associated HIV-1 RNA in the blood of aviremic
i n d i v i d u a l ss u g g e s t sar e s i d u al virus replication despite
undetectable HIV-1 plasma viral load. This observation
is in agreement with data clearly indicating that CD4
+ T
cells in which HIV-1 transcription occurs persist in per-
ipheral blood mononuclear cells from patients receiving
potent antiretroviral therapy [22,34,39,40].
We hypothesized that the HIV-1-AgSCs and cell-asso-
ciated HIV-1 RNA detected in breast milk from women
on ART reflected the production of virus from stable
reservoirs, such as the latent reservoir of resting CD4
+
T cells and perhaps macrophages. It can also be reason-
ably assumed that HIV-1-AgSCs and cell-associated
HIV-1 RNA do not originate from additional viral repli-
cation owing to the suppressive effect of ART. The virus
produced by the HIV-1 infected latent CD4
+ Tc e l l s
becomes detectable as cell-associated virus, but not as
cell-free virus, because of the low lymphocyte content of
breast milk. According to our results and considering
the estimated daily breast milk consumption [41], an
infant breastfed by an HIV-1-infected woman may
ingest an average of 178 HIV-1-AgSCs per day during
his/her first four months of life. As one HIV-1- replicat-
ing cell releases at least 1,000 viral particles [18,33], the
infant daily exposure could be around 178,000 cell-asso-
ciated HIV-1 RNA. Thus, babies fed on breast milk con-
taining no detectable cell-free virus may have their
mucosa exposed to high levels of HIV-1 particles spon-
taneously secreted by HIV-1 infected CD4
+ T cells. The
HIV-1-AgSCs described here may access the infant’s tis-
sues given that previous studies have shown immunolo-
gically active cells from breast milk infiltrating the
tissues of the intestinal tract of the recipient [26,42,43].
Cell associated viral particles in contact with mucosa
may penetrate to the submucosa through musal
breaches or via transcytosis through specific molecular
scaffolds and the molecular machinery of epithelial cells
[44].
Our data reinforce the findings of several previous
studies suggesting that latently HIV-1 infected cells are
an important source of mother to child-transmission
[9,14,15,20,45]. The ability of short-course antiretroviral
regimens to reduce the breast milk transmission could
be explained by effects of treatment on infectious virions
[46-51]. In contrast, ART may prove to be poorly
efficient at controlling cell-associated viral transmission
since: (i) cell-associated HIV-1 RNA levels in breast
milk are only modestly affected by ART [20], and (ii) we
detected HIV-1-AgSCs and cell-associated HIV-1 RNA
in women with undetectable HIV-1 plasma viral load. In
vitro infection of donor cells indicated that the virus
particles secreted into the cell culture supernatants from
breast milk cells are infectious. Taking into account the
low bioavailability of ritonavir/lopinavir in breast milk
[52], we assume that these protease inhibitors are unable
to suppress the release of infective virus from the HIV-1
cell reservoir in women receiving protease inhibitor-con-
taining regimens. By contrast, while most reverse tran-
scriptase inhibitors have a good bioavailability in breast
milk, they are only efficient on viruses undergoing new
cycles of infection. Thus, reverse transcriptase inhibitors
would not be effective at controlling viruses produced
from a stable reservoir. Recent results demonstrated
that HIV-1 transmission to breastfed babies is decreased
but not eliminated by maternal ART [48-53]. These
observations may reflect the interrelationship between
HIV-1 cell reservoirs, T cell activation, and antiretroviral
bioavailability in breast milk.
In conclusion, our study has shown that most CD4
+ T
cells in the breast milk of HIV-1 infected women are
activated memory cells, some of which are able to spon-
taneously produce HIV-1 antigens and virions in the
absence of in vitro activation. In women successfully
treated by ART during lactation, these cells can be
detected in both blood and breast milk despite undetect-
able levels of HIV-1 RNA in these compartments. These
results suggest that ART administered to HIV-1 infected
women during lactation is ineffective at suppressing
cell-associated virus replication and thus may incomple-
tely inhibit the breastfeeding transmission of HIV-1.
The evaluation of alternative prevention strategies
against the breastfeeding transmission of HIV-1 from
infected mothers, such as physical or chemical treatment
of extracted maternal milk or infant antiretroviral pro-
phylactic treatment throughout the breastfeeding period
needs consideration.
Methods
Study population and sample collection
This study was conducted at the Centre Muraz, Bobo-
Dioulasso, Burkina Faso and at the University of Mon-
tpellier 1, France. The study was approved by the Ethical
Committee of the Centre Muraz and the National Ethi-
cal Committee of the Ministry of Health, Burkina Faso,
and written informed consent was obtained from all
participants. Fifteen HIV-1 infected lactating women
volunteered to participate. The mean duration of lacta-
tion was 42.2 days (range 9-91 days). Immediately after
a feed, each woman provided 70 ml of breast milk, by
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levels were measured in the Centre Muraz, Bobo-Diou-
lasso using the Generic HIV Charge Viral kit, (Bio-
centric, Bandol, France) and ABI PRISM
® 7000
thermocycler (Applied Biosystems, Foster City, USA)
[32]. The lower limit of quantification (LLQ) of the test
was 300 HIV-1 RNA copies/ml. Fresh blood CD4
+ T
lymphocytes were enumerated by flow cytometry (Bec-
ton Dickinson, BD Bioscience, and San Jose, CA).
Isolation of breast milk CD4
+ T cells
Breast milk cells were separated as previously described
[54]. Breast milk samples were processed within 4 h of
collection. The acellular fraction (lactoserum and lipid
fraction) was removed by centrifugation at 1,200 g for
15 min. Breast milk cell pellets were washed three times
in PBS supplemented with 5% fetal calf serum (FCS)
and finally suspended in RPMI 1640 medium plus 10%
FCS, 2 mM L-glutamine, 100 U/ml penicillin, and 100
μg/ml streptomycin (complete medium, all reagents
from Eurobio). At least one fifth of the collected breast
milk cells were stored in liquid nitrogen before flow
cytometry analysis and the remaining cells were used for
CD4
+ T cell purification. Breast milk- and blood-derived
CD4
+ T lymphocytes were isolated by negative selection
using an immunorosetting method (Rosette SepTM
CD4 cell enrichment cocktail, Stemcell Technologies).
The cocktail used allows the cross linking of unwanted
leukocytes with red blood cells using antibodies directed
against CD8, CD16, CD19, CD36, CD56 and glyco-
phorin A. Red blood cells were prepared from 5 ml of
whole blood from healthy donors by centrifugation of
the sample for 10 min at 50 × g. They were then
washed three times in PBS-2% FCS before being re-sus-
pended in 1 ml of PBS-2% FCS. Red blood cell concen-
trates were kept at 4°C for 15 days to discard residual
blood leukocytes before being added to the breast milk
cell suspension. Red blood cells were then added to 3
ml of the breast milk cell suspension. When centrifuged
over the buoyant density medium, rosetted cells were
pelleted along with red blood cells. The enriched CD4
+T cells were recovered from the Ficoll-plasma interface,
washed three times in PBS/2% FCS and re-suspended at
a final concentration of 1 × 10
5cells/ml in culture com-
plete medium. This method resulted in the elimination
of 95% of non-T CD4
+ lymphocytes [54].
Isolation of blood CD4
+ T cells
Blood CD4
+ T cells were purified using an immunoro-
setting method (Rosette SepTM CD4
+ cell enrichment
cocktail, Stemcell Technologies) [32]. Purified CD4
+ T
cells were suspended in complete culture medium at a
final concentration of 1 × 10
6 cells/ml.
Flow cytometry analysis
The phenotypic characterization of breast milk and per-
ipheral blood mononuclear cells stored in liquid nitro-
gen was performed in the Montpellier laboratory using
Abs conjugated to fluorescein isothiocyanate (FITC),
phycoerythrin (PE/RD1), energy coupled dye (ECD), or
phycoerythrin cyanine 5 (PC5) directed to CD3, CD4,
CD8, CD38, CD45RA and HLA-DR cell-membrane
markers (Beckman-Coulter, Fullerton, CA). Stained cells
were analyzed using a FC-500 flow cytometer (Beck-
man-Coulter). The breast milk and blood T cell analyses
were based on a forward versus side scatter histogram
and CD3 positive events. Our design was to run 1,000
gated T cells. Percentages of CD4
+ and CD8
+ T cells in
breast milk and blood lymphocytes were estimated as
the percentage of CD3 positive events in the CD3-PC5
size histogram gate. The spontaneously activated CD4
+
T cell subset from breast milk was defined as the CD3
+,
CD4
+, CD45RA- T cells expressing HLA-DR and CD38
cell-surface markers.
HIV-1-Ag ELISpot assay
Immobilon-P membrane 96-well plates (MAIPN 4550,
Millipore Corporation, Bedford, MA) were coated over-
n i g h ta t4 ° Cw i t h1 0 0μlo fam i x t u r eo fa n t i - H I V - 1
polyclonal Abs prepared as previously described [32]. To
enumerate p24 spontaneously secreting cells, enriched
CD4
+ T cells from breast milk and blood were seeded
on the nitrocellulose plate for 18 h, at a concentration
of 1 × 10
5 CD4
+ T cells/100 μl per well. Immunospots
were analyzed and counted in the Montpellier labora-
tory by video camera imaging and computer-assisted
analysis (KS ELISPOT, Carl Zeiss, Jena, Germany), each
spot representing the fingerprint of one HIV-1-antigen
secreting cell (HIV-1- AgSC). Results were expressed as
the number of spots read/10
6 CD4
+ T cells tested. The
threshold for the lower limit of detection of HIV-1 Ag
cell secretion in this assay was established using mean
values obtained by testing breast milk and blood sam-
ples from 10 healthy controls uninfected by HIV-1
(mean + 2SD = 3 immunospots/10
6 cells).
Quantification of cell-free and cell-associated HIV-1 RNA
levels
Cell-associated HIV-1 RNA secretion was explored by
the quantification of HIV-1 RNA secreted by CD4
+ T
cells after a short culture period. Cell free virus was
investigated by measuring the HIV-1 RNA viral load in
lactoserum and plasma. Cell-free and cell-associated
HIV-1 RNA extraction from lactoserum/plasma and 18
h cell culture supernatants stored at -80°C were per-
formed in the Montpellier laboratory using the High
Pure Viral RNA Kit (Roche Diagnostics, Indianapolis,
IN), according to the manufacturer’s instructions.
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Page 9 of 12Samples were centrifuged 1 hour at 23,500 × g at 4°C
before RNA extraction. With this ultrasensitive protocol,
the LLQ was 60 HIV-1 RNA copies/ml. Supernatants
from 5 HIV-1 uninfected controls were below this
threshold.
Co-culturing of viral-culture supernatants with donor CD4
+ T cells
The infectivity of virus secreted into culture superna-
tants was tested after 18 h of incubation by coculturing
with CD4
+ T cells. Target CD4
+ T cells were obtained
from healthy blood donors within 24 h of donation.
CD4
+ T cells were enriched from whole blood by nega-
tive selection as described above and were activated for
48 hours with phytohemagglutinin (4 μg/ml) plus 10 U/
mL recombinant human IL-2 (Invitrogen, Grand Island,
NY) in complete culture medium. CD4
+ Tc e l l sf r o m
three different donors were combined for each culture.
Then, 2 × 10
5 activated CD4
+ T cells in 100 μlo fc u l -
ture media were cultivated with 100 μl of supernatant
for 14 days. Twice a week, culture medium above the
settled CD4
+ T cell was removed for HIV-1 RNA detec-
tion and replaced with an equal volume of complete cul-
ture medium.
Quantification of cell-associated HIV-1 DNA
After 18 hours of incubation, CD4
+ T cells were col-
lected and stored in liquid nitrogen in the Montpellier
laboratory before measuring the HIV-1 DNA levels
using an in-house real time PCR assay as previously
described [55]. To determine precisely the amount of
DNA in the purified CD4
+ T cells, all samples were
tested using LightCycler-Control kit DNA (Roche Diag-
nostics) that quantifies the human b-globin gene. All
samples from each woman were tested in the same
assay run and results were expressed as the number of
DNA copies/10
6 CD4
+ T cells tested.
Statistical analysis
The correlations between variables were analyzed by
Spearman’s rank test. Results were compared using the
Mann-Whitney U paired test. P values < 0.05 were con-
sidered statistically significant. A value equal to half the
threshold was allocated to undetectable supernatants (ie
30 HIV-1 RNA copies/ml).
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